Tag Archives: WHO

Will WHO Member States Pony Up for Neglected Diseases?

Recognizing that traditional market forces – namely incentives related to intellectual property and a steady demand for products – have failed in developing countries, the World Health Organization (WHO) asked a member state-nominated group to come up with ways to fund R&D and pay for the treatment of neglected diseases in the world’s poorest nations. […]
Posted in Emerging Markets, Global, IP, leadership, Legal, Manufacturing, Market Access, pricing, R&D | Also tagged , , , , , , , , , | Leave a comment

New Coalition Takes on Neglected Tropical Diseases

A new coalition for sharing pharma IP takes aim at the increasing burden of neglected tropical diseases in the developing world. According to the World Health Organization, neglected tropical diseases affect more than one billion of the world’s poorest 2.7 billion people. Many of these diseases, which can cause blindness and other debilitating symptoms, have […]
Posted in Corporate Responsibility, IP | Also tagged , , , , | Leave a comment

Industry, Patents and Public Health: Wimps on the Barbie?

The welcome news of a compact between industry and the WHO to fight neglected diseases in the developing world only highlights a much more spotty industry record of engagement on sensitive policy issues like intellectual property rights. One of the industry’s more ambitious policy-driven efforts occurred some five years ago with a strong, well-funded and […]
Posted in Corporate Responsibility, Global, Legal, R&D, Strategy | Also tagged , , , | 1 Comment

WHO Brings Big Pharma Together to Fight Debilitating Diseases

A new report from WHO on overcoming the impact of neglected tropical diseases has spawned a $150 million funding and donation initiative from Big Pharma. Last week, the World Health Organization (WHO) announced an initiative involving six Pharmaceutical companies—Novartis, GlaxoSmithKline, Sanofi-Aventis, Johnson & Johnson, Bayer, and Eisai of Japan—that will bring much-needed funding and research […]
Posted in Deals, Global, R&D | Tagged | 1 Comment

WHO Threatens Industry Shut-out on Counterfeit Regulation

Big Pharma believes that a global generics franchise might give it a softer landing off the patent cliff, but governments that sponsor and regulate the industry are still acting a bit slow on the uptake. The reason? Anti-IP activists are again poisoning the well on global access to medicines, engaging the bigger emerging market governments […]
Posted in Global | Also tagged , , , , , | Leave a comment
  • Categories

  • Meta